European Respiratory Journal

SCOPUS (1988-2023)SCIE-ISI

  0903-1936

  1399-3003

  Thụy Sĩ

Cơ quản chủ quản:  EUROPEAN RESPIRATORY SOC JOURNALS LTD , European Respiratory Society

Lĩnh vực:
Pulmonary and Respiratory MedicineMedicine (miscellaneous)

Các bài báo tiêu biểu

Standardisation of spirometry
Tập 26 Số 2 - Trang 319-338 - 2005
Martin R. Miller
Interpretative strategies for lung function tests
Tập 26 Số 5 - Trang 948-968 - 2005
Raffaello Pellegrino, Giovanni Viegi, Vito Brusasco, Robert O. Crapo, Felip Burgos, Richard Casaburi, Allan L. Coates, C.P.M. van der Grinten, Per Gustafsson, John Hankinson, Robert L. Jensen, David C. Johnson, Neil MacIntyre, Ryan T. McKay, Martin R. Miller, Daniel Navajas, Ole Pedersen, Jack Wanger
Lung volumes and forced ventilatory flows
Tập 6 Số Suppl 16 - Trang 5-40 - 1993
PH Quanjer, G. J. Tammeling, J. E. Cotes, Ole F. Pedersen, R Peslin, Yernault Jc
Multi-ethnic reference values for spirometry for the 3–95-yr age range: the global lung function 2012 equations
Tập 40 Số 6 - Trang 1324-1343 - 2012
Philip H. Quanjer, Sanja Stanojevic, Tim Cole, Xaver Baur, Graham L. Hall, Bruce H. Culver, Paul Enright, John Hankinson, Msm Ip, Jinping Zheng, Janet Stocks
International Study of Asthma and Allergies in Childhood (ISAAC): rationale and methods
Tập 8 Số 3 - Trang 483-491 - 1995
M. I. Asher, Ulrich Keil, H R Anderson, Richard Beasley, Julian Crane, Fernando D. Martínez, Ed Mitchell, Neil Pearce, Bonnie Sibbald, Alistair Stewart, D P Strachan, S K Weiland, Hywel C Williams

The aetiology of asthma and allergic disease remains poorly understood, despite considerable research. The International Study of Asthma and Allergies in Childhood (ISAAC), was founded to maximize the value of epidemiological research into asthma and allergic disease, by establishing a standardized methodology and facilitating international collaboration. Its specific aims are: 1) to describe the prevalence and severity of asthma, rhinitis and eczema in children living in different centres, and to make comparisons within and between countries; 2) to obtain baseline measures for assessment of future trends in the prevalence and severity of these diseases; and 3) to provide a framework for further aetiological research into genetic, lifestyle, environmental, and medical care factors affecting these diseases. The ISAAC design comprises three phases. Phase 1 uses core questionnaires designed to assess the prevalence and severity of asthma and allergic disease in defined populations. Phase 2 will investigate possible aetiological factors, particularly those suggested by the findings of Phase 1. Phase 3 will be a repetition of Phase 1 to assess trends in prevalence.

Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis
Tập 55 Số 5 - Trang 2000547 - 2020
Guan Wei, Wenhua Liang, Yi Zhao, Heng-rui Liang, Zi‐Sheng Chen, Yi Min Li, Xiaoqing Liu, Ru-chong Chen, Chun-li Tang, Tao Wang, Chun‐Quan Ou, Li Li, Ping Yan Chen, Ling Sang, Wei Wang, Jian-fu Li, Caichen Li, Li-min Ou, Bo Cheng, Shan Xiong, Zheng-yi Ni, Jie Xiang, Yu Hu, Lei Liu, Hong Shan, Chun-liang Lei, Yi-xiang Peng, Li Wei, Yong Liu, Ya Hu, Peng Peng, Jian Ming Wang, Jiyang Liu, Zhong Chen, Gang Li, Zhi Zheng, Shao-qin Qiu, Jie Luo, Chang-jiang Ye, Shao Zhu, Lin-ling Cheng, Feng Ye, Shi-yue Li, Jintao Zheng, Nuo-fu Zhang, Nan-shan Zhong, Jian-xing He
Background

The coronavirus disease 2019 (COVID-19) outbreak is evolving rapidly worldwide.

Objective

To evaluate the risk of serious adverse outcomes in patients with COVID-19 by stratifying the comorbidity status.

Methods

We analysed data from 1590 laboratory confirmed hospitalised patients from 575 hospitals in 31 provinces/autonomous regions/provincial municipalities across mainland China between 11 December 2019 and 31 January 2020. We analysed the composite end-points, which consisted of admission to an intensive care unit, invasive ventilation or death. The risk of reaching the composite end-points was compared according to the presence and number of comorbidities.

Results

The mean age was 48.9 years and 686 (42.7%) patients were female. Severe cases accounted for 16.0% of the study population. 131 (8.2%) patients reached the composite end-points. 399 (25.1%) reported having at least one comorbidity. The most prevalent comorbidity was hypertension (16.9%), followed by diabetes (8.2%). 130 (8.2%) patients reported having two or more comorbidities. After adjusting for age and smoking status, COPD (HR (95% CI) 2.681 (1.424–5.048)), diabetes (1.59 (1.03–2.45)), hypertension (1.58 (1.07–2.32)) and malignancy (3.50 (1.60–7.64)) were risk factors of reaching the composite end-points. The hazard ratio (95% CI) was 1.79 (1.16–2.77) among patients with at least one comorbidity and 2.59 (1.61–4.17) among patients with two or more comorbidities.

Conclusion

Among laboratory confirmed cases of COVID-19, patients with any comorbidity yielded poorer clinical outcomes than those without. A greater number of comorbidities also correlated with poorer clinical outcomes.

Global strategy for asthma management and prevention: GINA executive summary
Tập 31 Số 1 - Trang 143-178 - 2008
Eric D. Bateman, Suzanne S. Hurd, Peter J. Barnes, Jean Bousquet, Jeffrey M. Drazen, Mark Fitzgerald, Peter G. Gibson, K. Ohta, Paul M. O’Byrne, Søren Pedersen, Emílio Pizzichini, Sharon Sullivan-Rubin, Sally E. Wenzel, Heather J. Zar

Asthma is a serious health problem throughout the world. During the past two decades, many scientific advances have improved our understanding of asthma and ability to manage and control it effectively. However, recommendations for asthma care need to be adapted to local conditions, resources and services. Since it was formed in 1993, the Global Initiative for Asthma, a network of individuals, organisations and public health officials, has played a leading role in disseminating information about the care of patients with asthma based on a process of continuous review of published scientific investigations. A comprehensive workshop report entitled “A Global Strategy for Asthma Management and Prevention”, first published in 1995, has been widely adopted, translated and reproduced, and forms the basis for many national guidelines. The 2006 report contains important new themes. First, it asserts that “it is reasonable to expect that in most patients with asthma, control of the disease can and should be achieved and maintained,” and recommends a change in approach to asthma management, with asthma control, rather than asthma severity, being the focus of treatment decisions. The importance of the patient–care giver partnership and guided self-management, along with setting goals for treatment, are also emphasised.

Development and first validation of the COPD Assessment Test
Tập 34 Số 3 - Trang 648-654 - 2009
Paul Jones, Gale Harding, Pamela Berry, Ingela Wiklund, W-H. Chen, Nancy Kline Leidy
Standardisation of the measurement of lung volumes
Tập 26 Số 3 - Trang 511-522 - 2005
Jack Wanger, John A. Clausen, Allan L. Coates, Ole Pedersen, Vito Brusasco, Felip Burgos, Richard Casaburi, Robert O. Crapo, Paul Enright, C.P.M. van der Grinten, Per Gustafsson, John Hankinson, Robert L. Jensen, Douglas C. Johnson, Neil MacIntyre, Ryan T. McKay, Martin R. Miller, Daniel Navajas, Raffaello Pellegrino, Giovanni Viegi
Development and validation of a questionnaire to measure asthma control
Tập 14 Số 4 - Trang 902 - 1999
Elizabeth F. Juniper, Paul M. O’Byrne, Gordon Guyatt, P J Ferrie, Derek King